StackLeaf
Stock · NSE

ZYDUSLIFE

1,120.00 12.30 (1.11%)
Last 2 days · 15m candles25/8/2026, 00:35:38
Open: 1,109.20High: 1,120.00Low: 1,099.80Prev: 1,107.70
Positive
7
Neutral
17
Negative
6

News mentioning ZYDUSLIFE

Sentiment: +3%← All news
VERIFIEDET Finance·3d★ ON YOUR LIST
Zydus Lifesciences gets USFDA nod for generic ascorbic acid injection
AI summary· POSITIVE
  • ·Zydus Lifesciences has received final USFDA approval for its generic ascorbic acid injection.
  • ·The injection is approved for the treatment of scurvy in specific patient groups.
  • ·The USFDA designated this application as a Competitive Generic Therapy.
VERIFIEDET Finance·11d★ ON YOUR LIST
Delhi HC backs Zydus in trademark row
AI summary· POSITIVE
  • ·The Delhi High Court upheld a ruling against Alder Biochem regarding the 'Biochem' trademark.
  • ·Alder Biochem's argument that 'Biochem' is public property was dismissed by the court.
  • ·Zydus Healthcare's registered trademark, held since 1959, is protected by this decision.
VERIFIEDMint Markets·13d★ ON YOUR LIST
Q1 results 2026: RVNL to MRF among companies to declare Q1 results today; full list here
AI summary· NEUTRAL
  • ·Rail Vikas Nigam, MRF, Zydus Lifesciences, NBCC (India), Senco Gold, and Manappuram Finance will report their Q1 FY27 results today.
  • ·The companies are scheduled to declare their financial results for the first quarter of the fiscal year 2027.
  • ·This list includes a diverse range of sectors within the Indian stock market.
VERIFIEDMint Markets·33d★ ON YOUR LIST
Lupin, Sun Pharma to Cipla: Pharma stocks decline after Trump’s tariffs plan on generic medicines import
AI summary· NEGATIVE
  • ·Several Indian pharmaceutical companies experienced a decline in their stock prices.
  • ·Aurobindo Pharma, Ajanta Pharma, Lupin, Gland Pharma, and Zydus Lifesciences were among the top decliners.
  • ·The decline occurred following a plan by Donald Trump regarding tariffs on generic medicine imports.
VERIFIEDET Finance·44d★ ON YOUR LIST
Maharashtra FDA bars sale of two Cadila drugs over branding concerns
AI summary· NEGATIVE
  • ·Maharashtra FDA seized Cadila Pharmaceuticals drug stock worth Rs 2.45 crore.
  • ·Sales of Aciloc 150 Plus and Aciloc 300 Plus were barred due to similar branding on different active ingredients.
  • ·The action aims to prevent medication errors and safeguard public health.
VERIFIEDET Markets·56d★ ON YOUR LIST
Market Trading Guide: Finolex Cables among 2 stock recommendations for Tuesday
AI summary· POSITIVE
  • ·Domestic equities closed higher on positive Asian cues, falling crude oil prices and hopes of an India-US trade deal.
  • ·Analysts recommend buying Finolex Cables.
  • ·Analysts recommend buying Zydus Wellness, citing bullish technical setups, strong moving-average support and breakout patterns with upside potential.
VERIFIEDET Stocks·56d★ ON YOUR LIST
Market Trading Guide: Finolex Cables among 2 stock recommendations for Tuesday
AI summary· POSITIVE
  • ·Domestic equities closed higher on positive Asian cues, falling crude oil prices and hopes of an India-US trade deal.
  • ·Analysts recommend buying Finolex Cables.
  • ·Analysts recommend buying Zydus Wellness, citing bullish technical setups, strong moving-average support and breakout patterns with upside potential.
VERIFIEDET Finance·59d★ ON YOUR LIST
Zydus, Sunshine to set up $20 million pharma JV in Sri Lanka
AI summary· POSITIVE
  • ·Zydus Lifesciences and Sunshine Healthcare Lanka will form a $20 million joint venture.
  • ·The new entity, Zydus Sunshine Lifesciences, will establish a manufacturing facility in Sri Lanka's Horana Export Processing Zone.
  • ·The venture aims to increase local drug production and reduce import dependency.
VERIFIEDET Finance·69d★ ON YOUR LIST
Zydus Lifesciences completes acquisition of Assertio
AI summary· NEUTRAL
  • ·Zydus Lifesciences has completed the acquisition of Assertio Holdings Inc.
  • ·The acquisition was made through its wholly-owned subsidiary, Zara Merger Sub Inc.
  • ·The transaction involved a cash tender offer for all outstanding shares of Assertio's common stock.
VERIFIEDET Finance·82d★ ON YOUR LIST
Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns
AI summary· NEUTRAL
  • ·The Delhi High Court has directed the CDSCO to review a petition against Zydus Lifesciences' semaglutide injection approval.
  • ·A diabetes patient has raised concerns regarding the drug's delivery system, citing potential health risks.
  • ·The CDSCO is required to make a decision on the patient's representation within two months.